ABBV · News · 20260825N
Competition and Market Position
AbbVie Inc. · 2026-08-25 · Importance 13 · Surprise 6 · No source text
Eli Lilly is gaining momentum in obesity and diabetes through its GLP-1 therapies Mounjaro and Zepbound. AbbVie has offset Humira’s loss of exclusivity with immunology products Skyrizi and Rinvoq. The comparison characterizes Lilly as having a stronger growth trajectory, particularly in the expanding obesity and diabetes markets, while AbbVie remains supported by a diversified product portfolio and pipeline.
Key facts
- Convergence Financial LLC grew its position in AbbVie by 91.7% during the undefined quarter. source
- AbbVie reported a 10.20% revenue growth rate. source
- AbbVie has new immunology drugs Skyrizi and Rinvoq that helped the company navigate the loss of exclusivity for Humira. source
- After purchasing an additional 2,713 shares, Convergence Financial LLC owned 5,670 shares of AbbVie. source
- Analysts are largely bullish on AbbVie with a 4.39% upside potential. source
- AbbVie Inc. has a market capitalization of $468.22 billion. source
- AbbVie's stock is trading near its 52-week high. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +10.2% | AbbVie reported a 10.20% revenue growth rate. |